Rothblatt Martine A's Form 4 filing
United Therapeutics CorpUTHR · filed Nov 5, 2026
- Accession no.
- 0001106578-26-000180
- Filed
- Nov 5, 2026, 5:21 PM ET
- Trade date
- Nov 4, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $1.05M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rothblatt Martine ACIK 0001106578 | Director, Officer (Chairperson & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Common Stock | SSaleDisposed | −842 | $610.29F2 | −$513,866.54 | 325,324 | Indirect | |
| Nov 4, 2026 | Common Stock | SSaleDisposed | −403 | $611.26F4 | −$246,336.61 | 324,921 | Indirect | |
| Nov 4, 2026 | Common Stock | SSaleDisposed | −398 | $612.06F5 | −$243,600.04 | 324,523 | Indirect | |
| Nov 4, 2026 | Common Stock | SSaleDisposed | −80 | $613.14F6 | −$49,050.8 | 324,443 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $609.78 to $610.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $610.79 to $611.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $611.87 to $612.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $613.12 to $613.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Due to the 30 line limitation in Table 1, this report is being filed across two forms. This is the second of two filings.